SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Aoki N, Matsuda T. 2000. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 275: 3971839726.
  • Aoki N, Matsuda T, Saito H, Takatsuki K, Okajima K, Takahashi H, Takamatsu J, Asakura H, Ogawa N. 2002. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 75: 540547.
  • Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A, Kitamura T. 2000. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem 275: 2440724413.
  • Azam M, Erdjument-Bromage H, Kreider BL, Xia M, Quelle F, Basu R, Saris C, Tempst P, Ihle JN, Schindler C. 1995. Interleukin-3 signals through multiple isoforms of Stat5. EMBO J 14: 14021411.
  • Bao J, Zervos AS. 1996. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 12: 21712176.
  • Beuvink I, Hess D, Flotow H, Hofsteenge J, Groner B, Hynes NE. 2000. Stat5a serine phosphorylation. Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity. J Biol Chem 275: 1024710255.
  • Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19: 24742488.
  • Broadhurst MK, Wheeler TT. 2001. The p100 coactivator is present in the nuclei of mammary epithelial cells and its abundance is increased in response to prolactin in culture and in mammary tissue during lactation. J Endocrinol 171: 329337.
  • Brockman JL, Schroeder MD, Schuler LA. 2002. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 16: 774784.
  • Bromberg J. 2002. Stat proteins and oncogenesis. J Clin Invest 109: 11391142.
  • Buettner R, Mora LB, Jove R. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945954.
  • Cardiff RD, Wellings SR. 1999. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 4: 105122.
  • Chen Y, Wen R, Yang S, Schuman J, Zhang EE, Yi T, Feng GS, Wang D. 2003. Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 278: 1652016527.
  • Cheng SY. 2003. Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol 213: 2330.
  • Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278: 18031805.
  • Copeland NG, Gilbert DJ, Schindler C, Zhong Z, Wen Z, Darnell JE Jr, Mui AL, Miyajima A, Quelle FW, Ihle JN, et al. 1995. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29: 225228.
  • Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. 2004. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665671.
  • Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L. 2004. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24: 80378047.
  • Darnell JE, Jr. 1997. STATs and gene regulation. Science 277: 16301635.
  • Dickson RB, Lippman ME. 1995. Growth factors in breast cancer. Endocr Rev 16: 559589.
  • Favre-Young H, Dif F, Roussille F, Demeneix BA, Kelly PA, Edery M, de Luze A. 2000. Cross-talk between signal transducer and activator of transcription (Stat5) and thyroid hormone receptor-beta 1 (TRbeta1) signaling pathways. Mol Endocrinol 14: 14111424.
  • Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L. 2001. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol 229: 163175.
  • Gewinner C, Hart G, Zachara N, Cole R, Beisenherz-Huss C, Groner B. 2004. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 279: 35633572.
  • Gowri PM, Ganguly TC, Cao J, Devalaraja MN, Groner B, Vore M. 2001. Conversion of threonine 757 to valine enhances Stat5a transactivation potential. J Biol Chem 276: 1048510491.
  • Grimley PM, Dong F, Rui H. 1999. Stat5a and Stat5b: Fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 10: 131157.
  • Groner B. 2002. Transcription factor regulation in mammary epithelial cells. Domest Anim Endocrinol 23: 2532.
  • Groner B, Fritsche M, Stocklin E, Berchtold S, Merkle C, Moriggl R, Pfitzner E. 2000. Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. Growth Horm IGF Res 10 (Suppl B): S15S20.
  • Hansen JA, Lindberg K, Hilton DJ, Nielsen JH, Billestrup N. 1999. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 13: 18321843.
  • Haspel RL, Darnell JE, Jr. 1999. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. Proc Natl Acad Sci USA 96: 1018810193.
  • Haura EB, Turkson J, Jove R. 2005. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2: 315324.
  • Hendry L, John S. 2004. Regulation of STAT signalling by proteolytic processing. Eur J Biochem 271: 46134620.
  • Hennighausen L, Robinson GW. 2005. Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715725.
  • Horvath CM. 2000. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 25: 496502.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. 2002. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21: 88048816.
  • Humphreys RC, Hennighausen L. 1999. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10: 685694.
  • Hung LY, Tang CJ, Tang TK. 2000. Protein 4.1 R-135 interacts with a novel centrosomal protein (CPAP) which is associated with the gamma-tubulin complex. Mol Cell Biol 20: 78137825.
  • Hynes RO. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell 110: 673687.
  • Iavnilovitch E, Groner B, Barash I. 2002. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 1: 3247.
  • Iavnilovitch E, Cardiff RD, Groner B, Barash I. 2004. Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 112: 607619.
  • Iavnilovitch E, Eilon T, Groner B, Barash I. 2006. Expression of a carboxy-terminally-truncated Stat5 with no transactivation domain in the mammary glands of transgenic mice inhibits cell proliferation during pregnancy, delays onset of milk secretion and induces apoptosis upon involution. Mol Reprod Dev 73: 841849.
  • Ihle JN, Kerr IM. 1995. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11: 6974.
  • Iwase H. 2003. Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer 10: 8996.
  • John S, Vinkemeier U, Soldaini E, Darnell JE Jr, Leonard WJ. 1999. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol 19: 19101918.
  • Jones FE, Welte T, Fu XY, Stern DF. 1999. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 147: 7788.
  • Jung HH, Lee J, Kim JH, Ryu KJ, Kang SA, Park C, Sung K, Nam DH, Kang WK, Park K, Im YH. 2005. STAT1 and Nmi are downstream targets of Ets-1 transcription factor in MCF-7 human breast cancer cell. FEBS Lett 579: 39413946.
  • Kazansky AV, Raught B, Lindsey SM, Wang YF, Rosen JM. 1995. Regulation of mammary gland factor/Stat5a during mammary gland development. Mol Endocrinol 9: 15981609.
  • Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. 1999. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 274: 2248422492.
  • Keeton EK, Brown M. 2005. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19: 15431554.
  • Kirken RA, Malabarba MG, Xu J, Liu X, Farrar WL, Hennighausen L, Larner AC, Grimley PM, Rui H. 1997. Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem 272: 1409814103.
  • Kloth MT, Catling AD, Silva CM. 2002. Novel activation of STAT5b in response to epidermal growth factor. J Biol Chem 277: 86938701.
  • Kuroda H, Tamaru J, Takeuchi I, Ohnisi K, Sakamoto G, Adachi A, Kaneko K, Itoyama S. 2006. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch 448: 500505.
  • Levy DE, Darnell JE, Jr. 2002. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651662.
  • Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, Furth PA. 1997. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA 94: 34253430.
  • Li H, Lee TH, Avraham H. 2002. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 277: 2096520973.
  • Lin JX, Mietz J, Modi WS, John S, Leonard WJ. 1996. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem 271: 1073810744.
  • Lindeman GJ, Wittlin S, Lada H, Naylor MJ, Santamaria M, Zhang JG, Starr R, Hilton DJ, Alexander WS, Ormandy CJ, Visvader J. 2001. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev 15: 16311636.
  • Litterst CM, Kliem S, Marilley D, Pfitzner E. 2003. NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. J Biol Chem 278: 4534045351.
  • Litterst CM, Kliem S, Lodrini M, Pfitzner E. 2005. Coactivators in gene regulation by STAT5. Vitam Horm 70: 359386.
  • Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. 1995. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 92: 88318835.
  • Liu X, Robinson GW, Hennighausen L. 1996. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 10: 14961506.
  • Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. 1997. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11: 179186.
  • Magne S, Caron S, Charon M, Rouyez MC, Dusanter-Fourt I. 2003. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol Cell Biol 23: 89348945.
  • Malewski T. 1998. Computer analysis of distribution of putative cis- and trans-regulatory elements in milk protein gene promoters. Biosystems 45: 2944.
  • Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, Ihle JN. 1999. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98: 617627.
  • Maurer AB, Wichmann C, Gross A, Kunkel H, Heinzel T, Ruthardt M, Groner B, Grez M. 2002. The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 99: 26472652.
  • Medina D. 2005. Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 12: 483495.
  • Meyer J, Jucker M, Ostertag W, Stocking C. 1998. Carboxyl-truncated STAT5beta is generated by a nucleus-associated serine protease in early hematopoietic progenitors. Blood 91: 19011908.
  • Minoguchi S, Minoguchi M, Yoshimura A. 2003. Differential control of the NIMA-related kinases, Nek6 and Nek7, by serum stimulation. Biochem Biophys Res Commun 301: 899906.
  • Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L. 2001. Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 155: 531542.
  • Nakajima H, Brindle PK, Handa M, Ihle JN. 2001. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: Implications in negative regulation of STAT5-dependent transcription. EMBO J 20: 68366844.
  • Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. 2002. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 16: 11081124.
  • Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H. 2004. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22: 20532060.
  • Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. 1999. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274: 1720917218.
  • Park SH, Yamashita H, Rui H, Waxman DJ. 2001. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: Impact on STAT5 transcriptional activity. Mol Endocrinol 15: 21572171.
  • Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, Lisanti MP. 2002. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell 13: 34163430.
  • Paukku K, Yang J, Silvennoinen O. 2003. Tudor and nuclease-like domains containing protein p100 function as coactivators for signal transducer and activator of transcription 5. Mol Endocrinol 17: 18051814.
  • Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. 2004. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103: 37443750.
  • Pfitzner E, Jahne R, Wissler M, Stoecklin E, Groner B. 1998. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol 12: 15821593.
  • Pircher TJ, Flores-Morales A, Mui AL, Saltiel AR, Norstedt G, Gustafsson JA, Haldosen LA. 1997. Mitogen-activated protein kinase kinase inhibition decreases growth hormone stimulated transcription mediated by STAT5. Mol Cell Endocrinol 133: 169176.
  • Pircher TJ, Petersen H, Gustafsson JA, Haldosen LA. 1999. Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol Endocrinol 13: 555565.
  • Reddy EP, Korapati A, Chaturvedi P, Rane S. 2000. IL-3 signaling and the role of Src kinases, JAKs and STATs: A covert liaison unveiled. Oncogene 19: 25322547.
  • Ren S, Cai HR, Li M, Furth PA. 2002. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21: 43354339.
  • Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, Nicola NA, Metcalf D, Hilton DJ, Alexander WS. 2001. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 98: 93249329.
  • Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. 2003. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22: 46644674.
  • Rosen RL, Winestock KD, Chen G, Liu X, Hennighausen L, Finbloom DS. 1996. Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes. Blood 88: 12061214.
  • Rosen JM, Wyszomierski SL, Hadsell D. 1999. Regulation of milk protein gene expression. Annu Rev Nutr 19: 407436.
  • Russo J, Mailo D, Hu YF, Balogh G, Sheriff F, Russo IH. 2005. Breast differentiation and its implication in cancer prevention. Clin Cancer Res 11: 931s936s.
  • Rycyzyn MA, Clevenger CV. 2002. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99: 67906795.
  • Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. 2002. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239256.
  • Schorr K, Furth PA. 2000. Induction of bcl-xL expression in mammary epithelial cells is glucocorticoid-dependent but not signal transducer and activator of transcription 5-dependent. Cancer Res 60: 59505953.
  • Sekine Y, Yamamoto T, Yumioka T, Sugiyama K, Tsuji S, Oritani K, Shimoda K, Minoguchi M, Yoshimura A, Matsuda T. 2005. Physical and functional interactions between STAP-2/BKS and STAT5. J Biol Chem 280: 81888196.
  • Shah YM, Rowan BG. 2005. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19: 732748.
  • Shuai K, Liu B. 2003. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3: 900911.
  • Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67: 227264.
  • Starr R, Hilton DJ. 1998. SOCS: Suppressors of cytokine signalling. Int J Biochem Cell Biol 30: 10811085.
  • Stocklin E, Wissler M, Gouilleux F, Groner B. 1996. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 383: 726728.
  • Stoecklin E, Wissler M, Moriggl R, Groner B. 1997. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. Mol Cell Biol 17: 67086716.
  • Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B. 1999. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 69: 195204.
  • Strange R, Friis RR, Bemis LT, Geske FJ. 1995. Programmed cell death during mammary gland involution. Methods Cell Biol 46: 355368.
  • Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. 2005. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24: 746760.
  • Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93: 841850.
  • Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. 1997. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94: 72397244.
  • Vidarsson H, Mikaelsdottir EK, Rafnar T, Bertwistle D, Ashworth A, Eyfjord JE, Valgeirsdottir S. 2002. BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity. FEBS Lett 532: 247252.
  • Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH. 2002. An adjunct mammary epithelial cell population in parous females: Its role in functional adaptation and tissue renewal. Development 129: 13771386.
  • Wakao H, Gouilleux F, Groner B. 1994. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13: 21822191.
  • Wang Y, Cheng CH. 2004. ERalpha and STAT5a cross-talk: Interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation and DNA-binding. FEBS Lett 572: 238244.
  • Wang D, Moriggl R, Stravopodis D, Carpino N, Marine JC, Teglund S, Feng J, Ihle JN. 2000. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO J 19: 392399.
  • Wang RH, Yu H, Deng CX. 2004. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci USA 101: 1710817113.
  • Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S. 1999. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 18: 19001904.
  • Welcsh PL, Owens KN, King MC. 2000. Insights into the functions of BRCA1 and BRCA2. Trends Genet 16: 6974.
  • Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. 2002. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 8: 30653074.
  • Wittig I, Groner B. 2005. Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells. Curr Drug Targets Immune Endocr Metabol Disord 5: 449463.
  • Wu W, Pew T, Zou M, Pang D, Conzen SD. 2005. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280: 41174124.
  • Wyszomierski SL, Yeh J, Rosen JM. 1999. Glucocorticoid receptor/signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation. Mol Endocrinol 13: 330343.
  • Xia Z, Sait SN, Baer MR, Barcos M, Donohue KA, Lawrence D, Ford LA, Block AM, Baumann H, Wetzler M. 2001. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 25: 473482.
  • Xu J, Li Q. 2003. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17: 16811692.
  • Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. 1998. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279: 19221925.
  • Yamamoto T, Yumioka T, Sekine Y, Sato N, Minoguchi M, Yoshimura A, Matsuda T. 2003. Regulation of FcepsilonRI-mediated signaling by an adaptor protein STAP-2/BSK in rat basophilic leukemia RBL-2H3 cells. Biochem Biophys Res Commun 306: 767773.
  • Yamashita H, Iwase H. 2002. The role of Stat5 in estrogen receptor-positive breast cancer. Breast Cancer 9: 312318.
  • Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon JM, Hennighausen L, Kirken RA, Rui H. 2001. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 183: 151163.
  • Yokoyama N, Reich NC, Miller WT. 2001. Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res 21: 369378.
  • Yu CL, Jin YJ, Burakoff SJ. 2000. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J Biol Chem 275: 599604.
  • Zhu M, John S, Berg M, Leonard WJ. 1999. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96: 121130.